14 May 2019
Visiongain has launched a new pharma report Medical Devices Leader Series: Top In Vitro Diagnostics (IVD) Companies 2019-2029: Danaher Corporation, Abbott Laboratories, Bio-Rad Laboratories, Roche, Siemens AG, Sysmex, Other Companies.
The global in vitro diagnostics (IVD) market is estimated to have reached $69.2bn in 2018. In 2018, Visiongain notes that Big Pharma companies, namely Roche, Danaher and Siemens dominated the sector accounting for 42.4% of the global IVD market with combined revenue of $29.3bn.
The lead analyst of the report commented "In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions. This has been done primarily in response to increased competition to maintain or increase market share, and to solidify a company’s position in the market. Small innovative companies are providing new technologies which feed into the development of products by leading players. Such companies represent potential acquisition targets for corporations seeking opportunities."
Leading companies featured in the report include Abbott Laboratories, Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Inc., Danaher Corporation, Laboratory Corporation of America (LabCorp), QIAGEN, Roche, Siemens AG, Sysmex Corporation, Thermo Fisher Scientific and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.